secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2026-09-16T20:50:37+00:00
Accession:  0001493152-26-042934
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa Therapeutics appoints Robert J. Spiegel, M.D. to board of directors
--------------------------------------------------------------------------

- Appointment effective September 14, 2026; Dr. Spiegel serves until next election or earlier departure.
- Compensation follows Board of Directors Compensation Plan adopted August 15, 2026, per Q2 10-Q.
- No arrangements, family relationships, or Item 404(a) reportable transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315226042934/0001493152-26-042934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315226042934/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer